Last reviewed · How we verify
Individualized oral morphine
Individualized oral morphine is a Opioid analgesic Small molecule drug developed by Children's Hospital of Fudan University. It is currently FDA-approved for Moderate to severe pain in pediatric patients, Cancer pain in children. Also known as: Individualized group.
Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception and provide analgesia.
Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception and provide analgesia. Used for Moderate to severe pain in pediatric patients, Cancer pain in children.
At a glance
| Generic name | Individualized oral morphine |
|---|---|
| Also known as | Individualized group |
| Sponsor | Children's Hospital of Fudan University |
| Drug class | Opioid analgesic |
| Target | Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | FDA-approved |
Mechanism of action
Morphine is an opioid agonist that binds to mu, delta, and kappa opioid receptors throughout the nervous system. This binding modulates pain signal transmission and alters the emotional response to pain. The individualized formulation allows for dose customization based on patient-specific factors, particularly important in pediatric populations where dosing must be carefully titrated.
Approved indications
- Moderate to severe pain in pediatric patients
- Cancer pain in children
Common side effects
- Constipation
- Nausea
- Drowsiness
- Respiratory depression
- Dizziness
Key clinical trials
- Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (PHASE2)
- Individualized Analgesia for Pediatric Adenotonsillectomy (PHASE4)
- Dosing Intervals of Opioid Medication for Chronic Pain (PHASE4)
- Morphine to Maximize the Benefits of Exercise Training in COPD or ILD and Persistent Breathlessness (PHASE2)
- Enhanced Recovery After Surgery for Emergency Caesarean Deliveries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Individualized oral morphine CI brief — competitive landscape report
- Individualized oral morphine updates RSS · CI watch RSS
- Children's Hospital of Fudan University portfolio CI
Frequently asked questions about Individualized oral morphine
What is Individualized oral morphine?
How does Individualized oral morphine work?
What is Individualized oral morphine used for?
Who makes Individualized oral morphine?
Is Individualized oral morphine also known as anything else?
What drug class is Individualized oral morphine in?
What development phase is Individualized oral morphine in?
What are the side effects of Individualized oral morphine?
What does Individualized oral morphine target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor
- Manufacturer: Children's Hospital of Fudan University — full pipeline
- Therapeutic area: All drugs in Pain management
- Indication: Drugs for Moderate to severe pain in pediatric patients
- Indication: Drugs for Cancer pain in children
- Also known as: Individualized group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing